TY - JOUR
T1 - A murine model of antimetabolite-based, submyeloablative conditioning for bone marrow transplantation
T2 - Biologic insights and potential applications
AU - Goebel, W. Scott
AU - Pech, Nancy K.
AU - Meyers, Justin L.
AU - Srour, Edward F.
AU - Yoder, Mervin C.
AU - Dinauer, Mary C.
N1 - Funding Information:
We thank Dr. Karen E. Pollok for helpful discussions of the data, and Shari Upchurch for her expert assistance in preparing the manuscript. This work was supported by National Heart, Lung and Blood Institute (P01 HL53586), and the Riley Memorial Association. The Wells Center for Pediatric Research is a Center for Excellence in Molecular Hematology funded by the National Institute of Diabetes and Digestive and Kidney Diseases (P50 DK 49218). WSG was a William Kennedy Fellow of the National Childhood Cancer Foundation.
PY - 2004/12
Y1 - 2004/12
N2 - Nonmyeloablative conditioning regimens for marrow transplantation are desirable in many settings. Because repeated doses of the antimetabolite 5-fluorouracil (5-FU) decreases marrow long-term repopulating ability (LTRA) upon transplantation into lethally irradiated hosts, we hypothesized that mice given sequential doses of 5-FU (termed paired dose 5-FU) may permit substantial syngeneic marrow engraftment. C57Bl/6 or X-linked chronic granulomatous disease (X-CGD) mice were administered 5-FU (150 mg/kg) on days -5 and -1. Assessment of host marrow phenotype and repopulating ability occurred on day 0. Transplantation of syngeneic donor marrow occurred on day 0 or day +15. We confirmed that the number of Sca-1 +lin - cells and the LTRA of marrow from paired dose 5-FU-treated animals were diminished. C57Bl/6 hosts conditioned with paired doses of 5-FU followed by transplantation of 20 × 10 6 fresh B6.SJL marrow cells on day 0 displayed 44.9% ± 7.1% donor chimerism 2 months posttransplant, and 34.4% ± 8.6% donor chimerism 6 months posttransplant. In contrast, paired dose 5-FU-conditioned hosts transplanted with similar numbers of donor cells on day +15 exhibited only 3.4% ± 1.2% donor chimerism at 2 months. Paired dose 5-FU-conditioned X-CGD hosts transplanted with MSCV-m91Neo-transduced X-CGD marrow averaged 6.6% ± 2.3% (range, 4%-10%) NADPH oxidase-reconstituted neutrophils 12-16 months after transplant. These findings support the concept that impairment of host stem cell competitiveness may be an important mechanism for permitting engraftment of donor cells, and suggest that only a brief period of modest host stem cell impairment may be necessary to achieve substantial donor cell engraftment.
AB - Nonmyeloablative conditioning regimens for marrow transplantation are desirable in many settings. Because repeated doses of the antimetabolite 5-fluorouracil (5-FU) decreases marrow long-term repopulating ability (LTRA) upon transplantation into lethally irradiated hosts, we hypothesized that mice given sequential doses of 5-FU (termed paired dose 5-FU) may permit substantial syngeneic marrow engraftment. C57Bl/6 or X-linked chronic granulomatous disease (X-CGD) mice were administered 5-FU (150 mg/kg) on days -5 and -1. Assessment of host marrow phenotype and repopulating ability occurred on day 0. Transplantation of syngeneic donor marrow occurred on day 0 or day +15. We confirmed that the number of Sca-1 +lin - cells and the LTRA of marrow from paired dose 5-FU-treated animals were diminished. C57Bl/6 hosts conditioned with paired doses of 5-FU followed by transplantation of 20 × 10 6 fresh B6.SJL marrow cells on day 0 displayed 44.9% ± 7.1% donor chimerism 2 months posttransplant, and 34.4% ± 8.6% donor chimerism 6 months posttransplant. In contrast, paired dose 5-FU-conditioned hosts transplanted with similar numbers of donor cells on day +15 exhibited only 3.4% ± 1.2% donor chimerism at 2 months. Paired dose 5-FU-conditioned X-CGD hosts transplanted with MSCV-m91Neo-transduced X-CGD marrow averaged 6.6% ± 2.3% (range, 4%-10%) NADPH oxidase-reconstituted neutrophils 12-16 months after transplant. These findings support the concept that impairment of host stem cell competitiveness may be an important mechanism for permitting engraftment of donor cells, and suggest that only a brief period of modest host stem cell impairment may be necessary to achieve substantial donor cell engraftment.
UR - https://www.scopus.com/pages/publications/10044280530
U2 - 10.1016/j.exphem.2004.08.007
DO - 10.1016/j.exphem.2004.08.007
M3 - Article
C2 - 15588950
AN - SCOPUS:10044280530
SN - 0301-472X
VL - 32
SP - 1255
EP - 1264
JO - Experimental Hematology
JF - Experimental Hematology
IS - 12
ER -